Q3 2026 Alkem Laboratories Ltd Earnings Call Transcript
Key Points
- Alkem Laboratories Ltd (BOM:539523) reported a YoY revenue growth of 10.7% for Q3 FY26, with total revenue reaching INR37,368 million.
- The company's international sales grew by 26.6% YoY, indicating strong performance in overseas markets.
- The domestic market showed a growth of 5.5% YoY, with a focus on chronic business contributing to a strong growth trajectory.
- Alkem Laboratories Ltd (BOM:539523) has carved out its Alkem Wellness business as a separate entity, which is expected to enhance focus and growth.
- The company has entered the MedTech sector, which is a $10 billion market in India, with plans to achieve significant growth and EBITDA margins of 25% in the next four to five years.
- The company's net profit growth was only 1.6% YoY, indicating pressure on profitability.
- There was an exceptional item impact of INR528 million related to the notification by the government of India regarding labor codes, affecting financial results.
- The domestic generic business has been flattish this year, posing a challenge to overall growth.
- The company faces potential cost impacts due to the recent MIP announcement for Pen and its derivatives, which could affect margins.
- Alkem Laboratories Ltd (BOM:539523) has a debt of INR450 crores to INR500 crores at a high interest rate, which could impact future profitability.
Ladies and gentlemen, good day, and welcome to Alkem's Q3 FY26 results call hosted by Motilal Oswal Financial Services Limited.
(Operator Instructions) Please note that this conference is being recorded. I now hand the conference over to Mr. Tushar Manudhane from Motilal Oswal Financial Services Limited. Thank you, and over to you, sir.
Thanks, (inaudible) Ira. Good evening, and warm welcome for third-quarter FY26 earnings call of Alkem Laboratories.
From the management side, we have Mr. Sandeep Singh, Managing Director; Mr. Vikas Gupta, CEO; Mr. Nitin Agrawal, CFO; Mr. Kaustav Banarjee, CEO, Alkem MedTech; and Ms. Purvi Shah, Head of Investor Relations. Over to you, Purvi.
Thank you, Tushar. Good evening, everyone. On behalf of Alkem, we welcome you all to today's quarter three FY26 results call. Earlier today, we released the financial results, press release and results presentation
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
